Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
暂无分享,去创建一个
Shinichi Sasaki | Fumiyuki Takahashi | Tomoko Yamada | Kazuhisa Takahashi | F. Takahashi | Kazuhisa Takahashi | Motoyasu Kato | Takahiro Nakamura | Kana Kurokawa | Yusuke Ochi | Hiroaki Ihara | Motoyasu Kato | S. Sasaki | Y. Ochi | H. Ihara | K. Kurokawa | Takahiro I Nakamura | Tomoko Yamada | T. Yamada
[1] D. Shitrit,et al. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib. , 2019, American journal of physiology. Lung cellular and molecular physiology.
[2] Kevin J Anstrom,et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.
[3] G. Raghu,et al. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value , 2016, Lung.
[4] N. Hanna,et al. Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients , 2010, Clinical Cancer Research.
[5] J. Huggins,et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. , 2019, The Lancet. Respiratory medicine.
[6] R. Kaiser,et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] K. Tatsumi,et al. Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study , 2018, Drug design, development and therapy.
[8] Zhen-hua Li. [The treatment of idiopathic pulmonary fibrosis]. , 2007, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[9] R. D. du Bois,et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. , 2016, Respiratory medicine.
[10] P. Portincasa,et al. Drug‐induced enterocolitis: Prevention and management in primary care , 2018, Journal of digestive diseases.
[11] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[12] R. Okuda,et al. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis , 2017, Scientific Reports.
[13] A. Azuma. Safety management of treatment with nintedanib in clinical practice of IPF. , 2017, Respiratory investigation.
[14] B. Ryffel,et al. Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[15] Kenton M Sanders,et al. Interstitial cells of cajal as pacemakers in the gastrointestinal tract. , 2006, Annual review of physiology.
[16] Y. Sugiyama,et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials , 2017, Respirology.
[17] Takeshi Johkoh,et al. American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .
[18] Luca Richeldi,et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.
[19] Alexander Pautsch,et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.
[20] W. Allum,et al. Guidance on the management of diarrhoea during cancer chemotherapy. , 2014, The Lancet. Oncology.
[21] G J Roth,et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis , 2007, European Respiratory Journal.
[22] Shandra L. Protzko,et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.
[23] T. Baba,et al. Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience. , 2017, Respiratory investigation.
[24] H. Collard,et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.
[25] G. Jayson,et al. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. , 2018, Gynecologic oncology.